Biotech Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome August 28, 2026
Biotech BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals August 28, 2026
Biotech Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million August 28, 2026
Biotech HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma August 28, 2026
Biotech TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS August 27, 2026
Biotech AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn’s Disease August 27, 2026
Biotech Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases August 27, 2026
Biotech Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy August 26, 2026
Biotech JATT III Acquisition Corp Announces Pricing of $60,000,000 Initial Public Offering August 26, 2026